Bio-Techne Corporation Issues Correction to Dividend Notice for Investors

Bio-Techne Corporation Corrects Dividend Notice

In a recent update, Bio-Techne Corporation (NASDAQ: TECH) issued a correction concerning its previous announcement on dividends. The correction specifically addresses an error in the shareholder record date provided in the initial release, where it mistakenly stated August 17, 2026, as the date when shareholders would be recorded. The accurate date for shareholders of record is, in fact, August 24, 2026. Apart from this adjustment, all other aspects of the dividend notice remain unchanged.

The Board of Directors at Bio-Techne has confirmed a dividend distribution of $0.08 per share for the quarter ending June 30, 2026. Shareholders will receive this quarterly dividend on August 28, 2026, provided they are on record as of the newly corrected date of August 24, 2026. Going forward, the Board is set to evaluate the potential for cash dividends on a quarterly basis.

Based in Minnesota, Bio-Techne is recognized as a leader in the life sciences industry and has a notable history of half a century that emphasizes its commitment to supporting scientific advancements and diagnostic capabilities. The corporation provides an extensive range of high-quality reagents, analytical tools, and precision diagnostics, serving the needs of various professionals across scientific and medical fields.

Bio-Techne's product offerings are divided into three primary brands, namely RD Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, representing the comprehensive process from research discovery to clinical decision-making. With a robust presence featuring 34 locations across the globe and a workforce of around 3,000 employees, the company has shown promising growth. For the fiscal year of 2026, Bio-Techne reported over $1.2 billion in net sales, underscoring its market position and product demand.

The company boasts an extensive portfolio comprising over 500,000 products utilized by academic researchers, biopharmaceutical and biotechnology firms, as well as clinical diagnostic laboratories around the world. This global reach highlights the significant role Bio-Techne plays in the ongoing progress within the life sciences sector.

In recent communications, Bio-Techne emphasizes that its press releases may contain forward-looking statements under the Private Securities Litigation Reform Act, including projections regarding stock repurchases and other business operations. However, the company notes these statements carry inherent risks and uncertainties that might impact actual results.

Among the various factors influencing potential operational outcomes are market conditions, the introduction of new products, competition within the biotechnological sector, and ongoing economic challenges, including currency fluctuation impacts and supply chain pressures. As always, Bio-Techne aims to keep its investors and stakeholders promptly informed of any significant business developments or impending changes that may arise.

For additional insights and updates about Bio-Techne Corporation and its significant contributions to the life sciences industry, interested parties can visit their official website at www.bio-techne.com or connect with them on social media platforms such as LinkedIn, X (formerly known as Twitter), and YouTube.

As Bio-Techne continues to strengthen its presence and drive innovations, stakeholders look forward to seeing how these dividend corrections may align with the company's ongoing growth trajectory and commitment to enhancing the scientific community’s efforts.